Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,467 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Recruiting Phase 2 Interventional

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated Phase 1 Interventional

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

NCT01783431
View directory record Official record
Conditions
Melanoma
Interventions
Poly ICLC, leukapheresis
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rural Adult and Youth Sun Protection Study

NCT06439979
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer
Interventions
RAYS Intervention
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
3 Years to 7 Years
Enrollment
843 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
2
States / cities
Salt Lake City, Utah • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

NCT05660850
View directory record Official record
Conditions
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions
GDC-6599, GDC-6599-matching placebo, Mannitol
Drug · Other · Diagnostic Test
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Northridge, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis

NCT00440518
View directory record Official record
Conditions
Migraine
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
24
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Walnut Creek, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Phase 2 Interventional

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

NCT07625215
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
BAY 3670549, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

NCT00800176
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO4998452
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 23, 2026, 8:38 PM EDT
Completed No phase listed Observational

A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)

NCT05561647
View directory record Official record
Conditions
Short Bowel Syndrome (SBS)
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated Phase 2 Interventional Results available

Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

NCT00668785
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Jumper, J. Michael, M.D.
Individual
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 23, 2026, 8:38 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

NCT04973163
View directory record Official record
Conditions
Solid Tumors, KRAS Mutation
Interventions
BI 1823911, BI 1701963, Midazolam
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New York, New York • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging Biomarkers of Pancreatic Function and Disease

NCT05659147
View directory record Official record
Conditions
Pancreatitis, Diabetes Mellitus
Interventions
Research MRI without administration of intravenous secretin, Research MRI with administration of intravenous secretin, Genetic Sequencing, Blood Tests, Stool Tests, Survey Completion, Endoscopic pancreatic function tests (ePFTs), Secretin
Diagnostic Test · Genetic · Other + 1 more
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers

NCT00968487
View directory record Official record
Conditions
Healthy
Interventions
Lyophilized Plasma, Fresh Frozen Plasma
Biological · Other
Lead sponsor
HemCon Medical Technologies, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 23, 2026, 8:38 PM EDT
Active, not recruiting Not applicable Interventional

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)

NCT05172271
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions
MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation
Device · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
25 Years to 64 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

NCT03588299
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY2599023 (DTX201)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • Ann Arbor, Michigan • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated Phase 4 Interventional Results available

Study Evaluating The Safety Of Xyntha In Usual Care Settings

NCT00765726
View directory record Official record
Conditions
Hemophilia A
Interventions
Moroctocog alfa(AF-CC), Blood draw for laboratory testing
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 23, 2026, 8:38 PM EDT
Not listed Phase 2 Interventional

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

NCT03412643
View directory record Official record
Conditions
HER2-negative Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
43
States / cities
Colton, California • Miami Beach, Florida • Orlando, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated Early Phase 1 Interventional

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

NCT03454243
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
RXDX-106
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 23, 2026, 8:38 PM EDT
Not yet recruiting Phase 1 Interventional

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

NCT07221799
View directory record Official record
Conditions
Multiple Sclerosis, Neuropathic Pain
Interventions
glibenclamide, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen

NCT00633009
View directory record Official record
Conditions
Cutaneous Leishmaniasis
Interventions
Leishmania tropica Skin Test Antigen (LtSTA), Leishmania tropica Skin Test Antigen Placebo (Placebo)
Biological
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 23, 2026, 8:38 PM EDT
Active, not recruiting No phase listed Observational

Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative

NCT03910933
View directory record Official record
Conditions
Health Literacy, Anticoagulation
Interventions
elearning patient information
Other
Lead sponsor
University of Alberta
Other
Eligibility
Up to 18 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

NCT06740799
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Results available

Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat

NCT00402987
View directory record Official record
Conditions
Pharyngitis
Interventions
celecoxib, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 18 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 23, 2026, 8:38 PM EDT